Literature DB >> 26914772

Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools.

Roger Jelliffe1.   

Abstract

Acutely ill intensive care unit (ICU) patients often have large apparent volumes of distribution of drugs and, because of this, their drug clearance (CL) is usually also increased. 'Augmented renal Cl' is a current issue in the management of drug therapy for acutely ill and unstable ICU patients; however, Cl, the product of volume and the rate constant for excretion, describes only a theoretical volume of drug cleared per unit of time. Information of the actual rate of movement of the drug itself is obscured. It is suggested that the most useful clinical information is given by describing drug volume and elimination rate constant separately. This also permits better understanding of the patient's separate issues of fluid balance and drug elimination, especially when dialysis, renal replacement therapy, or extracorporeal membrane oxygenation (ECMO) may be used, and facilitates management of these two important separate clinical issues. Optimal management of drug therapy also requires optimal methods embodied in clinical software to describe drug behavior in these highly unstable patients, and considerably more data than for ordinary patients. The interacting multiple model (IMM) clinical software facilitates management of both fluid balance and drug therapy in these unstable patients. Illustrative cases are discussed, and new monitoring and management strategies are suggested. Like other ICU skills, physicians need to learn optimal tools for managing drug therapy in the ICU. Further work should help evaluate these new approaches.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914772     DOI: 10.1007/s40262-016-0369-4

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Authors:  David S Bayard; Roger W Jelliffe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

Review 3.  Antibiotic dose optimization in critically ill patients.

Authors:  M O Cotta; J A Roberts; J Lipman
Journal:  Med Intensiva       Date:  2015-09-26       Impact factor: 2.491

4.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

6.  Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

7.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

8.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

9.  Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care.

Authors:  P W Niemiec; M D Allo; C F Miller
Journal:  Arch Surg       Date:  1987-02
  9 in total
  4 in total

1.  Comment on: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools".

Authors:  Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

2.  Author's Reply to Proost: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients".

Authors:  Roger W Jelliffe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

3.  New Perspectives in Clinical Pharmacokinetics-1: the Importance of Updating the Teaching in Pharmacokinetics that both Clearance and Elimination Rate Constant Approaches Are Mathematically Proven Equally Valid.

Authors:  Roger Jelliffe; David Bayard
Journal:  AAPS J       Date:  2018-02-26       Impact factor: 4.009

4.  Expert Discussion of the Role of Rate Constant Versus Clearance Approaches to Define Drug Pharmacokinetics: Theoretical and Clinical Considerations.

Authors:  Marilyn N Martinez; Roger W Jelliffe; Johannes H Proost
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.